(Q26862904)

Peter Westervelt

series ordinal

2

1 reference

Journal of Hematology & Oncology

language of work or name

1 reference

13 December 2012

3 references

3 April 2019

22 July 2020

3 references

3 April 2019

22 July 2020

5

1 reference

page(s)

75

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

2 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

on focus list of Wikimedia project

22 July 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

The tumor lysis syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Tumor lysis syndrome developing intraoperatively

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Oncology: Fixed-Dose Rasburicase 6 mg for Hyperuricemia and Tumor Lysis Syndrome in High-Risk Cancer Patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Tumor lysis syndrome associated with chemotherapy in primary retroperitoneal soft tissue sarcoma by ex vivo ATP-based tumor chemo-sensitivity assay (ATP-TCA).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

New insights into the epidemiology of gout

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Optimizing management of tumor lysis syndrome in adults with hematologic malignancies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Pitfalls in predicting tumor lysis syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Tumour lysis syndrome: new therapeutic strategies and classification

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Spontaneous recurrent tumor lysis syndrome in breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Tumor lysis syndrome in solid tumors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Spontaneous acute tumor lysis syndrome with advanced gastric cancer

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

Tumor lysis syndrome: current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

Treatment of impending tumor lysis with single-dose rasburicase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Renal tubular damage in rasburicase: risks of alkalinisation

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544586

Tumor Lysis Syndrome After Treatment With Docetaxel for Non–Small-Cell Lung Cancer

28 November 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-75

21 January 2018

1 reference

12 December 2020

[Spontaneous tumor lysis syndrome in a patient with non-Hodgkin's lymphoma]

1 reference

12 December 2020

Hyperuricemic acute renal failure in disseminated carcinoma

1 reference

12 December 2020

Acute spontaneous tumor lysis syndrome

1 reference

12 December 2020

Acute spontaneous tumor lysis syndrome in a patient with squamous cell carcinoma of the lung

1 reference

12 December 2020

Hyperuricemic acute renal failure

1 reference

12 December 2020

Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy

1 reference

12 December 2020

Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer

1 reference

12 December 2020

Spontaneous tumor lysis syndrome in acute lymphoblastic leukemia

1 reference

12 December 2020

Spontaneous tumour lysis syndrome associated with non-Hodgkin's lymphoma--a case report

1 reference

12 December 2020

Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults

1 reference

12 December 2020

Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-8722-5-75

1 reference

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1756-8722-5-75

1 reference

PubMed publication ID

23237230

1 reference